Search research articles
Contact Us
Filters
Showing results (1-10 of 24) with videos related to
Page
of 3
Sort By:
Oncology (Williston Park, N.Y.)
|
March 16, 2007
Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies
Muhammad Wasif Saif, S Peter Kang, Edward Chu
Contemporary Clinical Trials
|
June 16, 2019
Testing monotherapy and combination therapy in one trial with biomarker consideration
Linda Z Sun, S Peter Kang, Cong Chen
Leukemia & Lymphoma
|
September 14, 2004
Presentation of extramedullary acute myelogenous leukemia as bilateral testicular masses: response to non-myeloablative allogeneic transplantation
S Peter Kang, Delong b Liu, Anila Qureshi, et al.
Journal for Immunotherapy of Cancer
|
August 20, 2015
Pembrolizumab
Leila Khoja, Marcus O Butler, S Peter Kang, et al.
Journal for Immunotherapy of Cancer
|
February 10, 2019
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Meihua Wang, Cong Chen, Thomas Jemielita, et al.
Journal of Hematology & Oncology
|
June 26, 2008
Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells
Fanglei You, Lisa A Roberts, S Peter Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2014
First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors
María Elena Elez, Josep Tabernero, David Geary, et al.
The Journal of Clinical Investigation
|
June 27, 2017
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers, Jared Lunceford, Michael Nebozhyn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 7, 2016
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma
Dirk Schadendorf, Reinhard Dummer, Axel Hauschild, et al.
JAMA Oncology
|
December 21, 2018
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study
Manish A Shah, Takashi Kojima, Daniel Hochhauser, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 24) with videos related to
Sort By:
Page
of 3
Oncology (Williston Park, N.Y.)
|
March 16, 2007
Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies
Muhammad Wasif Saif, S Peter Kang, Edward Chu
Contemporary Clinical Trials
|
June 16, 2019
Testing monotherapy and combination therapy in one trial with biomarker consideration
Linda Z Sun, S Peter Kang, Cong Chen
Leukemia & Lymphoma
|
September 14, 2004
Presentation of extramedullary acute myelogenous leukemia as bilateral testicular masses: response to non-myeloablative allogeneic transplantation
S Peter Kang, Delong b Liu, Anila Qureshi, et al.
Journal for Immunotherapy of Cancer
|
August 20, 2015
Pembrolizumab
Leila Khoja, Marcus O Butler, S Peter Kang, et al.
Journal for Immunotherapy of Cancer
|
February 10, 2019
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Meihua Wang, Cong Chen, Thomas Jemielita, et al.
Journal of Hematology & Oncology
|
June 26, 2008
Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells
Fanglei You, Lisa A Roberts, S Peter Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2014
First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors
María Elena Elez, Josep Tabernero, David Geary, et al.
The Journal of Clinical Investigation
|
June 27, 2017
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers, Jared Lunceford, Michael Nebozhyn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 7, 2016
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma
Dirk Schadendorf, Reinhard Dummer, Axel Hauschild, et al.
JAMA Oncology
|
December 21, 2018
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study
Manish A Shah, Takashi Kojima, Daniel Hochhauser, et al.
Page
of 3